Activist DOMA Escalates Proxy Battle, Alleges "Value Destruction" and Misleading Patent Claims
PCRX sits 26% above its 52-week low of $18.8 on light trading volume (0.4× avg).
Summary
Activist investor DOMA Perpetual Capital Management, holding a 7.5% stake, has intensified its proxy battle against Pacira BioSciences, accusing the current board of overseeing a decade of value destruction, misleading shareholders on patent protection, and refusing to explore a sale.
Key Events · Corporate Governance and Compliance · PCRX
-
Proxy Battle Escalation
Activist DOMA Perpetual Capital Management (7.5% stake) intensified its campaign against Pacira's board ahead of the June 9 annual meeting.
-
Allegations of Value Destruction
DOMA claims the current board has overseen a decade of poor shareholder returns, with the stock price down across all recent periods.
-
Patent Protection Concerns
DOMA alleges management is misleading investors about the strength of its patent portfolio for EXPAREL, which generates 80% of company revenue, and minimizing the risk of further legal losses.
-
Call for Strategic Review
DOMA contends the board is refusing to explore a company sale to protect their own positions, putting personal interests ahead of shareholder value.
Analysis · PCRX · Life Sciences
This filing from activist investor DOMA Perpetual Capital Management significantly escalates the ongoing proxy battle by presenting detailed criticisms of Pacira's management and board. DOMA alleges a decade of poor shareholder returns, misrepresentation of patent strength for EXPAREL (which accounts for 80% of revenue), and a failure to explore strategic alternatives like a sale. These claims, if gaining traction with shareholders, could lead to a change in board composition and a fundamental shift in the company's strategic direction, including a potential sale process. The annual meeting on June 9, 2026, will be a critical event.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.6% of the 317 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PCRX was trading at $23.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $931.5M. The 52-week trading range was $18.80 to $27.64. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.